|
1
|
Psyrri A, Arkadopoulos N, Vassilakopoulou
M, Smyrniotis V and Dimitriadis G: Pathways and targets in
hepatocellular carcinoma. Expert Rev of Anticancer Ther.
12:1347–1357. 2012. View Article : Google Scholar
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Almog N, Ma L, Schwager C, et al:
Consensus microRNAs governing the switch of dormant tumors to the
fast-growing angiogenic phenotype. PLoS One. 7:e440012012.
View Article : Google Scholar
|
|
5
|
Welker MW and Trojan J: Anti-angiogenesis
in hepatocellular carcinoma treatment: current evidence and future
perspectives. World J Gastroenterol. 17:3075–3081. 2011.PubMed/NCBI
|
|
6
|
Edeline J, Boucher E, Rolland Y, et al:
Comparison of tumor response by Response Evaluation Criteria in
Solid Tumors (RECIST) and modified RECIST in patients treated with
sorafenib for hepatocellular carcinoma. Cancer. 118:147–156. 2012.
View Article : Google Scholar
|
|
7
|
Zhai B and Sun XY: Mechanisms of
resistance to sorafenib and the corresponding strategies in
hepatocellular carcinoma. World J Hepatol. 5:345–352. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang Y, Zheng T, Song R, et al:
Hypoxia-mediated sorafenib resistance can be overcome by EF24
through Von Hippel-Lindau tumor suppressor-dependent HIF-1α
inhibition in hepatocellular carcinoma. Hepatology. 57:1847–1857.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Paez-Ribes M, Allen E, Hudock J, et al:
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell.
15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyahara K, Nouso K, Tomoda T, et al:
Predicting the treatment effect of sorafenib using serum
angiogenesis markers in patients with hepatocellular carcinoma. J
Gastroenterol Hepatol. 26:1604–1611. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Holash J, Maisonpierre PC, Compton D, et
al: Vessel cooption, regression and growth in tumors mediated by
angiopoietins and VEGF. Science. 284:1994–1998. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Augustin HG, Koh GY, Thurston G and
Alitalo K: Control of vascular morphogenesis and homeostasis
through the angiopoietin-Tie system. Nat Rev Mol Cell Biol.
10:165–177. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saharinen P, Bry M and Alitalo K: How do
angiopoietins Tie in with vascular endothelial growth factors? Cur
Opin Hematol. 17:198–205. 2010.
|
|
14
|
Boosani CS, Mannam AP, Cosgrove D, et al:
Regulation of COX-2 mediated signaling by alpha3 type IV
noncollagenous domain in tumor angiogenesis. Blood. 110:1168–1177.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang W, Xu CX, Hou GS, Chen YG, Xin JX and
Liu XX: Downregulation of tumstatin expression by overexpression of
ornithine decarboxylase. Oncol Rep. 30:2042–2048. 2013.PubMed/NCBI
|
|
16
|
Colorado PC, Torre A, Kamphaus G, et al:
Anti-angiogenic cues from vascular basement membrane collagen.
Cancer Res. 60:2520–2526. 2000.PubMed/NCBI
|
|
17
|
Maeshima Y, Sudhakar A, Lively JC, et al:
Tumstatin, an endothelial cell-specific inhibitor of protein
synthesis. Science. 295:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamamoto Y, Maeshima Y, Kitayama H, et al:
Tumstatin peptide, an inhibitor of angiogenesis, prevents
glomerular hypertrophy in the early stage of diabetic nephropathy.
Diabetes. 53:1831–1840. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Glick D, Barth S and Macleod KF:
Autophagy: cellular and molecular mechanisms. J Pathol. 221:3–12.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu H, Wang D, Zhang L, et al:
Upregulation of autophagy by hypoxia-inducible factor-1α promotes
EMT and metastatic ability of CD133+ pancreatic cancer
stem-like cells during intermittent hypoxia. Oncol Rep. 32:935–942.
2014.PubMed/NCBI
|
|
21
|
Dong X, Li R, Xiu P, et al: Meloxicam
executes its antitumor effects against hepatocellular carcinoma in
COX-2-dependent and -independent pathways. PLoS One. 9:e928642014.
View Article : Google Scholar
|
|
22
|
Roy A and Kolattukudy PE: Monocyte
chemotactic protein-induced protein (MCPIP) promotes inflammatory
angiogenesis via sequential induction of oxidative stress,
endoplasmic reticulum stress and autophagy. Cell Signal.
24:2123–2131. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sachdev U, Cui X, Hong G, et al: High
mobility group box 1 promotes endothelial cell angiogenic behavior
in vitro and improves muscle perfusion in vivo in response to
ischemic injury. J Vasc Surg. 55:180–191. 2012. View Article : Google Scholar
|
|
24
|
Nguyen TM, Subramanian IV, Kelekar A and
Ramakrishnan S: Kringle 5 of human plasminogen, an angiogenesis
inhibitor, induces both autophagy and apoptotic death in
endothelial cells. Blood. 109:4793–4802. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu B, Jarzynka MJ, Guo P, Imanishi Y,
Schlaepfer DD and Cheng SY: Angiopoietin 2 induces glioma cell
invasion by stimulating matrix metalloprotease 2 expression through
the alphavbeta1 integrin and focal adhesion kinase signaling
pathway. Cancer Res. 66:775–783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fagiani E and Christofori G: Angiopoietins
in angiogenesis. Cancer Lett. 328:18–26. 2013. View Article : Google Scholar
|
|
27
|
Felcht M, Luck R, Schering A, et al:
Angiopoietin-2 differentially regulates angiogenesis through TIE2
and integrin signaling. J Clin Invest. 122:1991–2005. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim KW, Paul P, Qiao J and Chung DH:
Autophagy mediates paracrine regulation of vascular endothelial
cells. Lab Invest. 93:639–645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kimura S, Fujita N, Noda T and Yoshimori
T: Monitoring autophagy in mammalian cultured cells through the
dynamics of LC3. Methods Enzymol. 452:1–12. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eikesdal HP, Sugimoto H, Birrane G, et al:
Identification of amino acids essential for the antiangiogenic
activity of tumstatin and its use in combination antitumor
activity. Proc Natl Acad Sci USA. 105:15040–15045. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Giannotta M, Trani M and Dejana E:
VE-cadherin and endothelial adherens junctions: active guardians of
vascular integrity. Dev Cell. 26:441–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thomas M and Augustin HG: The role of the
angiopoietins in vascular morphogenesis. Angiogenesis. 12:125–137.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mazzieri R, Pucci F, Moi D, et al:
Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis
by impairing angiogenesis and disabling rebounds of proangiogenic
myeloid cells. Cancer Cell. 19:512–526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rini B, Szczylik C, Tannir NM, et al: AMG
386 in combination with sorafenib in patients with metastatic clear
cell carcinoma of the kidney: a randomized, double-blind,
placebo-controlled, phase 2 study. Cancer. 118:6152–6161. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hashizume H, Falcon BL, Kuroda T, et al:
Complementary actions of inhibitors of angiopoietin-2 and VEGF on
tumor angiogenesis and growth. Cancer Res. 70:2213–2223. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chae SS, Kamoun WS, Farrar CT, et al:
Angiopoietin-2 interferes with anti-VEGFR2-induced vessel
normalization and survival benefit in mice bearing gliomas. Clin
Cancer Res. 16:3618–3627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wendel HG, De Stanchina E, Fridman JS, et
al: Survival signalling by Akt and eIF4E in oncogenesis and cancer
therapy. Nature. 428:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Holopainen T, Saharinen P, D’Amico G, et
al: Effects of angiopoietin-2-blocking antibody on endothelial
cell-cell junctions and lung metastasis. J Natl Cancer Inst.
104:461–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Levine B and Kroemer G: Autophagy in the
pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
